Mesothelioma Cancer Centers
The Fred Hutchinson Cancer Research Center is a nonprofit, independent cancer research institute located in Seattle, Washington. The center’s researchers — who include three Nobel laureates, a MacArthur fellow, and several members of the Institute of Medicine and the Academy of Arts and Sciences — seek "the elimination of cancer and related diseases as causes of human suffering and death.” While Fred Hutch does not see patients, it is a vital part of the Seattle Cancer Care Alliance and the larger cancer-fighting medical community. The Fred Hutchinson Cancer Research Center specializes in lung cancer research, including prevention, detection and treatment. Founded in 1975, the center dedicates its time to researching complex cancers with more than 2,700 employees.
The center made advancements in detecting lung cancers, identifying proteins in blood that can help for early detection. In 2011, Fred Hutch researchers developed of a new blood test for cancer patients that is so sensitive it can detect the presence of tumors before other known detection methods. The tool could help save lives through early detection. The center’s scientists are also working to understand the roots of the disease: how and why normal cells change into cancerous cells, as well as how medicine could help prevent that from occurring. Lifestyle choices are another area of study to understand what may result in a cancers like mesothelioma, such as occupation. Immunotherapy remains a focus at the center, as they are discovering new ways to extract white blood cells from a patient’s own tumor and utilize it as a treatment method for cancer. Their expert researches also explore and identify proteins and genes that may make certain tumors grow and expand at faster rates than others.
The center formed the Seattle Cancer Care Alliance (SCCA), which includes affiliates UW Medicine and Seattle Children's Hospital, making the alliance the only National Cancer Institute-designated comprehensive cancer center in the Pacific Northwest. Today, an SCCA outpatient center sits on Fred Hutch’s main campus. The alliance serves as a leading cancer center in the country. They offer clinical care to patients who are being treated at the affiliated hospitals. Through this program, the center also offers clinical trials for a number of cancers, including mesothelioma.
- Genetic therapy
- National Cancer Institute (NCI) Comprehensive Cancer Center
- National Comprehensive Cancer Network accreditation
- Association for the Accreditation of Human Research Protection Programs accreditation
Mesothelioma Clinical Trials at Fred Hutchinson Cancer Research Center
The following clinical trials are in progress or actively recruiting participants at Fred Hutchinson Cancer Research Center:
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
Conditions: Biphasic Mesothelioma; Epithelioid Mesothelioma; Stage I Pleural Malignant Mesothelioma AJCC v7; Stage IA Pleural Malignant Mesothelioma AJCC v7; Stage IB Pleural Malignant Mesothelioma AJCC v7; Stage II Pleural Malignant Mesothelioma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7 Last Updated: May 9, 2019 Status: Recruiting
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Epithelioid Mesothelioma; Pleural Malignant Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma Last Updated: January 16, 2019 Status: Active, not recruiting
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Conditions: Advanced Pleural Malignant Mesothelioma; HLA-A*0201 Positive Cells Present; Recurrent Non-Small Cell Lung Carcinoma; Recurrent Pleural Malignant Mesothelioma; Stage III Non-Small Cell Lung Cancer AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non-Small Cell Lung Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7; Stage IV Pleural Malignant Mesothelioma AJCC v7; WT1 Positive Last Updated: June 7, 2018 Status: Active, not recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette